RU2594282C2 - Средства, вызывающие апоптоз, для лечения злокачественных новообразований и иммунных и аутоиммунных заболеваний - Google Patents

Info

Publication number

RU2594282C2

RU2594282C2 RU2014119254/04A RU2014119254A RU2594282C2 RU 2594282 C2 RU2594282 C2 RU 2594282C2 RU 2014119254/04 A RU2014119254/04 A RU 2014119254/04A RU 2014119254 A RU2014119254 A RU 2014119254A RU 2594282 C2 RU2594282 C2 RU 2594282C2

Authority

RU

Russia

Prior art keywords

benzothiazol

dihydroisoquinolin

ylcarbamoyl

carboxylic acid

methyl

Prior art date

2011-10-14

Links

• Espacenet
• Global Dossier
• Discuss

• 201000011510 cancer Diseases 0.000 title abstract description 16
• 206010028980 Neoplasm Diseases 0.000 title abstract description 15
• 230000006907 apoptotic process Effects 0.000 title description 13
• 208000023275 Autoimmune disease Diseases 0.000 title description 3
• 208000026278 immune system disease Diseases 0.000 title 1
• -1 tetrahydropiranyl Chemical group 0.000 claims abstract description 585
• 125000000217 alkyl group Chemical group 0.000 claims abstract description 279
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 217
• 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 159
• 229910052731 fluorine Inorganic materials 0.000 claims abstract description 143
• 229910052801 chlorine Inorganic materials 0.000 claims abstract description 142
• 229910052740 iodine Inorganic materials 0.000 claims abstract description 124
• 229910052794 bromium Inorganic materials 0.000 claims abstract description 123
• 150000001875 compounds Chemical class 0.000 claims abstract description 113
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract description 108
• 125000005873 benzo[d]thiazolyl group Chemical group 0.000 claims abstract description 104
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 102
• 229910052736 halogen Inorganic materials 0.000 claims abstract description 100
• 150000002367 halogens Chemical class 0.000 claims abstract description 91
• 239000001257 hydrogen Substances 0.000 claims abstract description 78
• 150000003839 salts Chemical class 0.000 claims abstract description 64
• 150000002431 hydrogen Chemical class 0.000 claims abstract description 38
• 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims abstract description 37
• 238000000034 method Methods 0.000 claims abstract description 29
• 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims abstract description 21
• 125000004076 pyridyl group Chemical group 0.000 claims abstract description 17
• 125000003226 pyrazolyl group Chemical group 0.000 claims abstract description 15
• 125000001425 triazolyl group Chemical group 0.000 claims abstract description 15
• 125000002757 morpholinyl group Chemical group 0.000 claims abstract description 14
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract description 5
• 125000005940 1,4-dioxanyl group Chemical group 0.000 claims abstract description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
• 125000003386 piperidinyl group Chemical group 0.000 claims abstract 10
• 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims abstract 4
• 229910052799 carbon Inorganic materials 0.000 claims description 266
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 151
• 125000001424 substituent group Chemical group 0.000 claims description 151
• 229910004013 NO 2 Inorganic materials 0.000 claims description 101
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
• SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 32
• 210000004027 cell Anatomy 0.000 claims description 28
• 239000002253 acid Substances 0.000 claims description 25
• 239000003814 drug Substances 0.000 claims description 25
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 17
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
• 125000003545 alkoxy group Chemical group 0.000 claims description 16
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 15
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 15
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 15
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 15
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 14
• 229940124597 therapeutic agent Drugs 0.000 claims description 14
• 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims description 12
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 11
• 206010005003 Bladder cancer Diseases 0.000 claims description 10
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 10
• 206010006187 Breast cancer Diseases 0.000 claims description 10
• 208000026310 Breast neoplasm Diseases 0.000 claims description 10
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 10
• 206010009944 Colon cancer Diseases 0.000 claims description 10
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 10
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 10
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 10
• 206010033128 Ovarian cancer Diseases 0.000 claims description 10
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 10
• 208000000389 T-cell leukemia Diseases 0.000 claims description 10
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 10
• 201000006491 bone marrow cancer Diseases 0.000 claims description 10
• 201000010881 cervical cancer Diseases 0.000 claims description 10
• 201000004101 esophageal cancer Diseases 0.000 claims description 10
• 201000003444 follicular lymphoma Diseases 0.000 claims description 10
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 10
• 208000014018 liver neoplasm Diseases 0.000 claims description 10
• 208000003747 lymphoid leukemia Diseases 0.000 claims description 10
• 201000001441 melanoma Diseases 0.000 claims description 10
• 208000025113 myeloid leukemia Diseases 0.000 claims description 10
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 10
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 10
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 10
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
• 206010060862 Prostate cancer Diseases 0.000 claims description 9
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
• 208000000277 Splenic Neoplasms Diseases 0.000 claims description 8
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
• 201000002471 spleen cancer Diseases 0.000 claims description 8
• 208000003445 Mouth Neoplasms Diseases 0.000 claims description 7
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 7
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
• PCJOKOQMKUYYRS-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(1-methoxy-3,3-dimethylcyclohexyl)methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(OC)CCCC(C)(C)C1 PCJOKOQMKUYYRS-UHFFFAOYSA-N 0.000 claims description 5
• XCEIRVRTIKSVJV-UHFFFAOYSA-N 3-(1-benzhydrylpyrazol-4-yl)-6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1C(C=1C=CC=CC=1)C1=CC=CC=C1 XCEIRVRTIKSVJV-UHFFFAOYSA-N 0.000 claims description 4
• BBSLYPVPSREFAC-UHFFFAOYSA-N 3-(1-benzylpyrazol-4-yl)-6-[8-[(5,6-difluoro-1,3-benzothiazol-2-yl)carbamoyl]-3,4-dihydro-1h-isoquinolin-2-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC(F)=C(F)C=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1 BBSLYPVPSREFAC-UHFFFAOYSA-N 0.000 claims description 4
• SSNNJLLRMCLVSF-UHFFFAOYSA-N 3-(1-benzylpyrazol-4-yl)-6-[8-[(6-fluoro-1,3-benzothiazol-2-yl)carbamoyl]-3,4-dihydro-1h-isoquinolin-2-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC(F)=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1 SSNNJLLRMCLVSF-UHFFFAOYSA-N 0.000 claims description 4
• NPQULOMUJADAKF-UHFFFAOYSA-N 3-(1-benzylpyrazol-4-yl)-6-[8-[(6-methoxy-1,3-benzothiazol-2-yl)carbamoyl]-3,4-dihydro-1h-isoquinolin-2-yl]pyridine-2-carboxylic acid Chemical compound S1C2=CC(OC)=CC=C2N=C1NC(=O)C(C=1C2)=CC=CC=1CCN2C(N=C1C(O)=O)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1 NPQULOMUJADAKF-UHFFFAOYSA-N 0.000 claims description 4
• RZBQGRFSPSOIJX-UHFFFAOYSA-N 3-(1-benzylpyrazol-4-yl)-6-[8-[(7-chloro-1,3-benzothiazol-2-yl)carbamoyl]-3,4-dihydro-1h-isoquinolin-2-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=C(Cl)C=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1 RZBQGRFSPSOIJX-UHFFFAOYSA-N 0.000 claims description 4
• XERRVYFCMVQPEG-UHFFFAOYSA-N 3-[1-(benzenesulfonyl)pyrrol-3-yl]-6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=CN1S(=O)(=O)C1=CC=CC=C1 XERRVYFCMVQPEG-UHFFFAOYSA-N 0.000 claims description 4
• BUTLYSQOBKRKIW-UHFFFAOYSA-N 3-[3-[2-(1-adamantyl)pyrrolidin-1-yl]-2-cyanophenyl]-6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)C=3C=CC=C4CCN(CC4=3)C=3N=C(C(=CC=3)C=3C(=C(N4C(CCC4)C45CC6CC(CC(C6)C4)C5)C=CC=3)C#N)C(=O)O)=NC2=C1 BUTLYSQOBKRKIW-UHFFFAOYSA-N 0.000 claims description 4
• DBTVIWQUZGEFFG-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-[(1-methylcyclohexyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1CC2=CC=CC(C(=O)NC=3SC4=CC=CC=C4N=3)=C2C(C)N1C(N=C1C(O)=O)=CC=C1C(=C1C)C=NN1CC1(C)CCCCC1 DBTVIWQUZGEFFG-UHFFFAOYSA-N 0.000 claims description 4
• JWUCDNZVXPLSJC-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzoylpyrrol-3-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=CN1C(=O)C1=CC=CC=C1 JWUCDNZVXPLSJC-UHFFFAOYSA-N 0.000 claims description 4
• DWSHQEMBIHVGII-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzyl-3-carboxy-5-methylpyrazol-4-yl)pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C(O)=O)=NN1CC1=CC=CC=C1 DWSHQEMBIHVGII-UHFFFAOYSA-N 0.000 claims description 4
• HIVZUGQRQKLYTK-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzyl-3-ethoxycarbonyl-5-methylpyrazol-4-yl)pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C(=O)OCC)=NN1CC1=CC=CC=C1 HIVZUGQRQKLYTK-UHFFFAOYSA-N 0.000 claims description 4
• HMDJUGGGZMLBPA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzyl-3-methylpyrazol-4-yl)pyridine-2-carboxylic acid Chemical compound C1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=NN1CC1=CC=CC=C1 HMDJUGGGZMLBPA-UHFFFAOYSA-N 0.000 claims description 4
• VRCSDEAAFWOOAL-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzyl-5-carboxy-2-methylpyrrol-3-yl)pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=C(C(O)=O)N1CC1=CC=CC=C1 VRCSDEAAFWOOAL-UHFFFAOYSA-N 0.000 claims description 4
• OHYXBKHOZFSEQF-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzyl-5-cyano-2-methylpyrrol-3-yl)pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=C(C#N)N1CC1=CC=CC=C1 OHYXBKHOZFSEQF-UHFFFAOYSA-N 0.000 claims description 4
• DCHXJHQLHSYQHK-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzyl-5-ethoxycarbonyl-2-methylpyrrol-3-yl)pyridine-2-carboxylic acid Chemical compound CCOC(=O)C1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1=CC=CC=C1 DCHXJHQLHSYQHK-UHFFFAOYSA-N 0.000 claims description 4
• IVYAPAVPDRSPOG-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzyl-5-methylpyrazol-4-yl)pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1=CC=CC=C1 IVYAPAVPDRSPOG-UHFFFAOYSA-N 0.000 claims description 4
• RFBGVAGVGHOAQN-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzyl-5-phenylpyrazol-4-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1C=2C=CC=CC=2)C=NN1CC1=CC=CC=C1 RFBGVAGVGHOAQN-UHFFFAOYSA-N 0.000 claims description 4
• NMKBDYBTAFPYQG-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzylpyrazol-4-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1 NMKBDYBTAFPYQG-UHFFFAOYSA-N 0.000 claims description 4
• YGLJYVHIEPGHAJ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzylpyrrol-3-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=CN1CC1=CC=CC=C1 YGLJYVHIEPGHAJ-UHFFFAOYSA-N 0.000 claims description 4
• LSVXVZQLNGDGSL-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzylpyrrolo[2,3-b]pyridin-3-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C1=CC=CN=C11)=CN1CC1=CC=CC=C1 LSVXVZQLNGDGSL-UHFFFAOYSA-N 0.000 claims description 4
• CBHXLAKEKNTGEO-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzylpyrrolo[2,3-c]pyridin-3-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C1=CC=NC=C11)=CN1CC1=CC=CC=C1 CBHXLAKEKNTGEO-UHFFFAOYSA-N 0.000 claims description 4
• CGCFTJMFUFDJFT-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-phenylpyrazol-4-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1C1=CC=CC=C1 CGCFTJMFUFDJFT-UHFFFAOYSA-N 0.000 claims description 4
• FAMBFQFMBAKJJE-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(2-cyclohexyloxy-3-methylpyridin-4-yl)pyridine-2-carboxylic acid Chemical compound N1=CC=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=C1OC1CCCCC1 FAMBFQFMBAKJJE-UHFFFAOYSA-N 0.000 claims description 4
• POSGOGLWVNQEAX-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(2-cyclohexyloxypyridin-4-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=1)=CC=NC=1OC1CCCCC1 POSGOGLWVNQEAX-UHFFFAOYSA-N 0.000 claims description 4
• PUZDRMIYSZPIAZ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(2-methyl-3-phenoxyphenyl)pyridine-2-carboxylic acid Chemical compound C1=CC=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=C1OC1=CC=CC=C1 PUZDRMIYSZPIAZ-UHFFFAOYSA-N 0.000 claims description 4
• ZWLMAMIIWMIKLS-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(2-methyl-4-phenoxyphenyl)pyridine-2-carboxylic acid Chemical compound C=1C=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=CC=1OC1=CC=CC=C1 ZWLMAMIIWMIKLS-UHFFFAOYSA-N 0.000 claims description 4
• CPNRNAHDRAHJCZ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(2-methyl-5-phenoxyphenyl)pyridine-2-carboxylic acid Chemical compound C1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=CC=C1OC1=CC=CC=C1 CPNRNAHDRAHJCZ-UHFFFAOYSA-N 0.000 claims description 4
• YIMLRZTXRJIWFO-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(2-phenoxypyridin-4-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=1)=CC=NC=1OC1=CC=CC=C1 YIMLRZTXRJIWFO-UHFFFAOYSA-N 0.000 claims description 4
• QLBWCJRXBWLAFR-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(3-benzylphenyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=1)=CC=CC=1CC1=CC=CC=C1 QLBWCJRXBWLAFR-UHFFFAOYSA-N 0.000 claims description 4
• YKHIMPDWJUHMMS-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(3-cyclohexyloxy-2-fluorophenyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=1F)=CC=CC=1OC1CCCCC1 YKHIMPDWJUHMMS-UHFFFAOYSA-N 0.000 claims description 4
• TYGAXWIAOOLCIA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(3-cyclohexyloxy-2-methylphenyl)pyridine-2-carboxylic acid Chemical compound C1=CC=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=C1OC1CCCCC1 TYGAXWIAOOLCIA-UHFFFAOYSA-N 0.000 claims description 4
• XVNMJABZHQBULE-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(3-methyl-2-phenoxypyridin-4-yl)pyridine-2-carboxylic acid Chemical compound N1=CC=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=C1OC1=CC=CC=C1 XVNMJABZHQBULE-UHFFFAOYSA-N 0.000 claims description 4
• NEPHNFIHXJIMPF-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(3-phenoxyphenyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=1)=CC=CC=1OC1=CC=CC=C1 NEPHNFIHXJIMPF-UHFFFAOYSA-N 0.000 claims description 4
• YLOKXSOZVCIHGX-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(4-cyclohexyloxy-2-methylphenyl)pyridine-2-carboxylic acid Chemical compound C=1C=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=CC=1OC1CCCCC1 YLOKXSOZVCIHGX-UHFFFAOYSA-N 0.000 claims description 4
• PALSTDWPMINOGA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(4-methyl-3-phenoxyphenyl)pyridine-2-carboxylic acid Chemical compound CC1=CC=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=C1OC1=CC=CC=C1 PALSTDWPMINOGA-UHFFFAOYSA-N 0.000 claims description 4
• ZURIGSUJWGWHHA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(4-phenoxyphenyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=C1)=CC=C1OC1=CC=CC=C1 ZURIGSUJWGWHHA-UHFFFAOYSA-N 0.000 claims description 4
• SKHSPSKRCVMLKT-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(1-cyclohexyl-3-methoxypropyl)-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1C(CCOC)C1CCCCC1 SKHSPSKRCVMLKT-UHFFFAOYSA-N 0.000 claims description 4
• LVWZPYXHXGZIOC-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(1-cyclohexyl-3-morpholin-4-ylpropyl)-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1C(C1CCCCC1)CCN1CCOCC1 LVWZPYXHXGZIOC-UHFFFAOYSA-N 0.000 claims description 4
• FTJLNNCJPJCARI-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(1-phenylethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1C(C)C1=CC=CC=C1 FTJLNNCJPJCARI-UHFFFAOYSA-N 0.000 claims description 4
• LCCKVNXYMGVDQL-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(2,2-dimethylpropyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=NN(CC(C)(C)C)C=C1C1=CC=C(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)N=C1C(O)=O LCCKVNXYMGVDQL-UHFFFAOYSA-N 0.000 claims description 4
• PDMPXJMUNXTDJX-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(2,3-dihydro-1h-inden-1-yl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)C=3C=CC=C4CCN(CC4=3)C=3N=C(C(=CC=3)C3=CN(N=C3)C3C4=CC=CC=C4CC3)C(=O)O)=NC2=C1 PDMPXJMUNXTDJX-UHFFFAOYSA-N 0.000 claims description 4
• KBAMPYFUEMHYOQ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(2-cyclohexyl-1-phenylethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1C(C=1C=CC=CC=1)CC1CCCCC1 KBAMPYFUEMHYOQ-UHFFFAOYSA-N 0.000 claims description 4
• GTLYUTZKCGNYMV-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(2-cyclohexylethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CCC1CCCCC1 GTLYUTZKCGNYMV-UHFFFAOYSA-N 0.000 claims description 4
• ZCDUVQIBTXDADX-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(2-methoxy-2-oxo-1-phenylethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1C(C(=O)OC)C1=CC=CC=C1 ZCDUVQIBTXDADX-UHFFFAOYSA-N 0.000 claims description 4
• TXNMLIXZSZEDAH-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(2-phenylethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CCC1=CC=CC=C1 TXNMLIXZSZEDAH-UHFFFAOYSA-N 0.000 claims description 4
• WBFUNUVJZPCLPK-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(3,4-dihydro-2h-chromen-4-yl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)C=3C=CC=C4CCN(CC4=3)C=3N=C(C(=CC=3)C3=CN(N=C3)C3C4=CC=CC=C4OCC3)C(=O)O)=NC2=C1 WBFUNUVJZPCLPK-UHFFFAOYSA-N 0.000 claims description 4
• LYFWWUYMRMCXHA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(3-methoxy-1-phenylpropyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1C(CCOC)C1=CC=CC=C1 LYFWWUYMRMCXHA-UHFFFAOYSA-N 0.000 claims description 4
• MPYLKMUWAMOGSA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(3-morpholin-4-yl-1-phenylpropyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1C(C=1C=CC=CC=1)CCN1CCOCC1 MPYLKMUWAMOGSA-UHFFFAOYSA-N 0.000 claims description 4
• XCAYLVULFKHTMI-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(4-methoxy-1-phenylbutyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1C(CCCOC)C1=CC=CC=C1 XCAYLVULFKHTMI-UHFFFAOYSA-N 0.000 claims description 4
• ALDUXXXGKSMWEL-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(4-methylphenyl)sulfonylpyrrol-3-yl]pyridine-2-carboxylic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=C1 ALDUXXXGKSMWEL-UHFFFAOYSA-N 0.000 claims description 4
• TVJXTXUMENZRDB-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(cyclohexylmethyl)-5-cyclopropylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1C2CC2)C=NN1CC1CCCCC1 TVJXTXUMENZRDB-UHFFFAOYSA-N 0.000 claims description 4
• UERLGZLALBYNQQ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(cyclohexylmethyl)-5-ethylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CCC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1CCCCC1 UERLGZLALBYNQQ-UHFFFAOYSA-N 0.000 claims description 4
• CISUFXVSHKYRMS-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(cyclohexylmethyl)-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1CCCCC1 CISUFXVSHKYRMS-UHFFFAOYSA-N 0.000 claims description 4
• WIUZIFAJBSZCKI-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(cyclohexylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1CCCCC1 WIUZIFAJBSZCKI-UHFFFAOYSA-N 0.000 claims description 4
• MSSHVCBRCSPEEH-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(cyclopentylmethyl)-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1CCCC1 MSSHVCBRCSPEEH-UHFFFAOYSA-N 0.000 claims description 4
• KNQJMTMRQNFGAJ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(naphthalen-2-ylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)C=3C=CC=C4CCN(CC4=3)C=3N=C(C(=CC=3)C3=CN(CC=4C=C5C=CC=CC5=CC=4)N=C3)C(=O)O)=NC2=C1 KNQJMTMRQNFGAJ-UHFFFAOYSA-N 0.000 claims description 4
• BCHUMHCNABWKFT-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(oxan-2-ylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1CCCCO1 BCHUMHCNABWKFT-UHFFFAOYSA-N 0.000 claims description 4
• RYLYKMUOJBVPPS-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(oxan-3-ylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1CCCOC1 RYLYKMUOJBVPPS-UHFFFAOYSA-N 0.000 claims description 4
• OGRLPJUBIXNDQT-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(pyridin-2-ylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=N1 OGRLPJUBIXNDQT-UHFFFAOYSA-N 0.000 claims description 4
• KFWWHDXQQKVMHS-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(pyridin-3-ylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CN=C1 KFWWHDXQQKVMHS-UHFFFAOYSA-N 0.000 claims description 4
• WBCFKELVKOCTOB-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(pyridin-4-ylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=NC=C1 WBCFKELVKOCTOB-UHFFFAOYSA-N 0.000 claims description 4
• HFGPGDMPFNZLFE-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(1-methoxy-3,3-dimethylcyclohexyl)methyl]-5-methyltriazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=NC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(OC)CCCC(C)(C)C1 HFGPGDMPFNZLFE-UHFFFAOYSA-N 0.000 claims description 4
• OZWINUTYNCUQQL-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(1-methoxycyclohexyl)methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(OC)CCCCC1 OZWINUTYNCUQQL-UHFFFAOYSA-N 0.000 claims description 4
• DUIDJJWLULSDGN-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(1-phenylcyclohexyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1(C=2C=CC=CC=2)CCCCC1 DUIDJJWLULSDGN-UHFFFAOYSA-N 0.000 claims description 4
• WUCSEAOOASXYPE-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2,3-difluorophenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC(F)=C1F WUCSEAOOASXYPE-UHFFFAOYSA-N 0.000 claims description 4
• NSFRBMGAIZKIDV-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2,5-difluorophenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC(F)=CC=C1F NSFRBMGAIZKIDV-UHFFFAOYSA-N 0.000 claims description 4
• VNKXQOCVVJIDLY-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2,6-difluorophenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=C(F)C=CC=C1F VNKXQOCVVJIDLY-UHFFFAOYSA-N 0.000 claims description 4
• BHWVVHIVIDBMRE-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2-chlorophenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1Cl BHWVVHIVIDBMRE-UHFFFAOYSA-N 0.000 claims description 4
• XVCDJVSXLWPQPT-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2-fluorophenyl)methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1=CC=CC=C1F XVCDJVSXLWPQPT-UHFFFAOYSA-N 0.000 claims description 4
• NBTDCSYMCVHVNA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2-hydroxyphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1O NBTDCSYMCVHVNA-UHFFFAOYSA-N 0.000 claims description 4
• HDOLYTQWDFKQRB-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2-morpholin-4-ylphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1N1CCOCC1 HDOLYTQWDFKQRB-UHFFFAOYSA-N 0.000 claims description 4
• ODFZPPOXPFFJGT-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2-nitrophenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1[N+]([O-])=O ODFZPPOXPFFJGT-UHFFFAOYSA-N 0.000 claims description 4
• WTTWVVSGLLCMKY-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2-phenylmethoxyphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1OCC1=CC=CC=C1 WTTWVVSGLLCMKY-UHFFFAOYSA-N 0.000 claims description 4
• IDTUNBRGOGGIIH-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2-phenylphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1C1=CC=CC=C1 IDTUNBRGOGGIIH-UHFFFAOYSA-N 0.000 claims description 4
• FBNOTYUPKOESRP-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3,3-dimethyl-1-morpholin-4-ylcyclohexyl)methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(N2CCOCC2)CCCC(C)(C)C1 FBNOTYUPKOESRP-UHFFFAOYSA-N 0.000 claims description 4
• XDCXMFFOTDHZLV-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3,5-difluorophenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC(F)=CC(F)=C1 XDCXMFFOTDHZLV-UHFFFAOYSA-N 0.000 claims description 4
• SHDQWTWPWDUGBD-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3,5-ditert-butylphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(CN2N=CC(=C2)C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 SHDQWTWPWDUGBD-UHFFFAOYSA-N 0.000 claims description 4
• QHUOKCSYRBRCEQ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3-chlorophenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC(Cl)=C1 QHUOKCSYRBRCEQ-UHFFFAOYSA-N 0.000 claims description 4
• YGDQXXYIDGSSFU-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3-cyanophenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC(C#N)=C1 YGDQXXYIDGSSFU-UHFFFAOYSA-N 0.000 claims description 4
• GPSWVVSZOULEBI-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3-formylphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC(C=O)=C1 GPSWVVSZOULEBI-UHFFFAOYSA-N 0.000 claims description 4
• YOWJICZVDQJENS-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3-hydroxyphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC(O)=C1 YOWJICZVDQJENS-UHFFFAOYSA-N 0.000 claims description 4
• XRKPVJRSOYCWEM-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3-methoxyphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound COC1=CC=CC(CN2N=CC(=C2)C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 XRKPVJRSOYCWEM-UHFFFAOYSA-N 0.000 claims description 4
• WIPYJTKJNLKGHM-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3-methylphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=CC=CC(CN2N=CC(=C2)C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 WIPYJTKJNLKGHM-UHFFFAOYSA-N 0.000 claims description 4
• FCPPSFAMJWHYMT-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3-methylsulfonylphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CS(=O)(=O)C1=CC=CC(CN2N=CC(=C2)C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 FCPPSFAMJWHYMT-UHFFFAOYSA-N 0.000 claims description 4
• GMTUXTDJDGUMAP-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3-phenylmethoxyphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC(C=1)=CC=CC=1OCC1=CC=CC=C1 GMTUXTDJDGUMAP-UHFFFAOYSA-N 0.000 claims description 4
• TVRPYMRYYVUXHU-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3-phenylphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC(C=1)=CC=CC=1C1=CC=CC=C1 TVRPYMRYYVUXHU-UHFFFAOYSA-N 0.000 claims description 4
• LMZHBWGNZZCTAM-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(4,4-difluorocyclohexyl)methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1CCC(F)(F)CC1 LMZHBWGNZZCTAM-UHFFFAOYSA-N 0.000 claims description 4
• AJGOBNYOWYWZFB-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(4-chlorophenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=C(Cl)C=C1 AJGOBNYOWYWZFB-UHFFFAOYSA-N 0.000 claims description 4
• QRHGHYAKVNINDB-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(4-fluoro-3-nitrophenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=C(F)C([N+]([O-])=O)=C1 QRHGHYAKVNINDB-UHFFFAOYSA-N 0.000 claims description 4
• VGZOLYGHENQJGT-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(4-hydroxyphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=C(O)C=C1 VGZOLYGHENQJGT-UHFFFAOYSA-N 0.000 claims description 4
• LTEDVMOGBGJUTC-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(6-pyrrolidin-1-ylpyridin-2-yl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC(N=1)=CC=CC=1N1CCCC1 LTEDVMOGBGJUTC-UHFFFAOYSA-N 0.000 claims description 4
• FPPVUNITBXXJOB-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[2-(4-fluorophenyl)ethyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CCC1=CC=C(F)C=C1 FPPVUNITBXXJOB-UHFFFAOYSA-N 0.000 claims description 4
• RDACNCBPXZAVNA-NHTMILBNSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[(1r,4r,5r)-5-bicyclo[2.2.1]hept-2-enyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)C=3C=CC=C4CCN(CC4=3)C3=CC=C(C(=N3)C(O)=O)C=3C=NN(C=3C)C[C@@H]3C[C@]4(C[C@]3([H])C=C4)[H])=NC2=C1 RDACNCBPXZAVNA-NHTMILBNSA-N 0.000 claims description 4
• PGQJDPDISMQODA-CTVOUCONSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[(1r,4r,5r)-6,6-dimethyl-4-bicyclo[3.1.1]heptanyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)C=3C=CC=C4CCN(CC4=3)C3=CC=C(C(=N3)C(O)=O)C=3C=NN(C=3C)C[C@H]3[C@]4(C[C@@](CC3)(C4(C)C)[H])[H])=NC2=C1 PGQJDPDISMQODA-CTVOUCONSA-N 0.000 claims description 4
• PGQJDPDISMQODA-MOMDTQCHSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[(1s,4r,5s)-6,6-dimethyl-4-bicyclo[3.1.1]heptanyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)C=3C=CC=C4CCN(CC4=3)C3=CC=C(C(=N3)C(O)=O)C=3C=NN(C=3C)C[C@H]3[C@@]4(C[C@](CC3)(C4(C)C)[H])[H])=NC2=C1 PGQJDPDISMQODA-MOMDTQCHSA-N 0.000 claims description 4
• QSGKDORZHUZXTA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(1,4-dioxan-2-ylmethoxy)cycloheptyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(OCC2OCCOC2)CCCCCC1 QSGKDORZHUZXTA-UHFFFAOYSA-N 0.000 claims description 4
• HCPOGQMRHPKHMP-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2,3-dihydroxypropoxy)cycloheptyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(OCC(O)CO)CCCCCC1 HCPOGQMRHPKHMP-UHFFFAOYSA-N 0.000 claims description 4
• CGTIQFGPEXLTCC-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2,3-dimethoxypropoxy)cycloheptyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(OCC(COC)OC)CCCCCC1 CGTIQFGPEXLTCC-UHFFFAOYSA-N 0.000 claims description 4
• QTDHFNWYZXYUOP-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2-hydroxyethoxy)cyclohexyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(OCCO)CCCCC1 QTDHFNWYZXYUOP-UHFFFAOYSA-N 0.000 claims description 4
• GPVLSNWOQCOTPG-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2-methoxyethoxy)-3,3-dimethylcyclohexyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(OCCOC)CCCC(C)(C)C1 GPVLSNWOQCOTPG-UHFFFAOYSA-N 0.000 claims description 4
• OIZAZUADGGNDRA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2-methoxyethoxy)cycloheptyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(OCCOC)CCCCCC1 OIZAZUADGGNDRA-UHFFFAOYSA-N 0.000 claims description 4
• LNEMGYZRVYYAQA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2-methoxyethoxy)cyclohexyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(OCCOC)CCCCC1 LNEMGYZRVYYAQA-UHFFFAOYSA-N 0.000 claims description 4
• NGTYPVHIIBMRLE-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2-methoxyethyl)-3,3-dimethylcyclohexyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(CCOC)CCCC(C)(C)C1 NGTYPVHIIBMRLE-UHFFFAOYSA-N 0.000 claims description 4
• DGPHUOWUXMACOK-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2-methoxyethyl)cycloheptyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(CCOC)CCCCCC1 DGPHUOWUXMACOK-UHFFFAOYSA-N 0.000 claims description 4
• BZVJZYSEYABPKC-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2-methoxyethyl)cyclohexyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(CCOC)CCCCC1 BZVJZYSEYABPKC-UHFFFAOYSA-N 0.000 claims description 4
• DFOALIBDSDZYOG-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2-methoxyethyl)cyclohexyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(CCOC)CCCCC1 DFOALIBDSDZYOG-UHFFFAOYSA-N 0.000 claims description 4
• MVQZRHWCVRNVCZ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(2-methylpropyl)cyclohexyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(CC(C)C)CCCCC1 MVQZRHWCVRNVCZ-UHFFFAOYSA-N 0.000 claims description 4
• BYQVJPGCJWFEQC-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(3-methoxypropyl)cycloheptyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(CCCOC)CCCCCC1 BYQVJPGCJWFEQC-UHFFFAOYSA-N 0.000 claims description 4
• QITBVHNBMQPGPQ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(3-methoxypropyl)cyclohexyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(CCCOC)CCCCC1 QITBVHNBMQPGPQ-UHFFFAOYSA-N 0.000 claims description 4
• GYJQPIDQQVZSBA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(methoxymethyl)cyclohexyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(COC)CCCCC1 GYJQPIDQQVZSBA-UHFFFAOYSA-N 0.000 claims description 4
• DODOFCVXBIOAIP-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-(trifluoromethyl)cyclohexyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1(C(F)(F)F)CCCCC1 DODOFCVXBIOAIP-UHFFFAOYSA-N 0.000 claims description 4
• QXAJITKMXDFUJL-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CN1N=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 QXAJITKMXDFUJL-UHFFFAOYSA-N 0.000 claims description 4
• UKSNYCREWBUSKN-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[2-(1,4-dioxan-2-ylmethoxy)phenyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1=CC=CC=C1OCC1COCCO1 UKSNYCREWBUSKN-UHFFFAOYSA-N 0.000 claims description 4
• UFFDCIFWKCFSNV-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[2-(2-methoxyethoxy)phenyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound COCCOC1=CC=CC=C1CN1C(C)=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=N1 UFFDCIFWKCFSNV-UHFFFAOYSA-N 0.000 claims description 4
• HTSMAYIADJQPMN-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[2-(2-morpholin-4-ylethoxy)phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1OCCN1CCOCC1 HTSMAYIADJQPMN-UHFFFAOYSA-N 0.000 claims description 4
• CWKCZWBDOSDNCC-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1C(C)(C)CCC(CN2N=CC(=C2)C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1C1=CC=C(Cl)C=C1 CWKCZWBDOSDNCC-UHFFFAOYSA-N 0.000 claims description 4
• XQIIDBWQRVEUTH-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[2-(dimethylamino)phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CN(C)C1=CC=CC=C1CN1N=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 XQIIDBWQRVEUTH-UHFFFAOYSA-N 0.000 claims description 4
• RVHDSUDURZKADA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[2-(pyridin-4-ylmethoxy)phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1OCC1=CC=NC=C1 RVHDSUDURZKADA-UHFFFAOYSA-N 0.000 claims description 4
• ALICWMMZNVIACQ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[2-[2-(dimethylamino)ethoxy]phenyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CN(C)CCOC1=CC=CC=C1CN1C(C)=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=N1 ALICWMMZNVIACQ-UHFFFAOYSA-N 0.000 claims description 4
• ORMVVIKLYQZJSF-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[2-[2-(dimethylamino)ethoxy]phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CN(C)CCOC1=CC=CC=C1CN1N=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 ORMVVIKLYQZJSF-UHFFFAOYSA-N 0.000 claims description 4
• CAPFUCBHTFYKQQ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[2-[3-(dimethylamino)propoxy]phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CN(C)CCCOC1=CC=CC=C1CN1N=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 CAPFUCBHTFYKQQ-UHFFFAOYSA-N 0.000 claims description 4
• DRZFSIXAJSILHC-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[2-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]phenyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1=CC=CC=C1OCC(C)(CO)CO DRZFSIXAJSILHC-UHFFFAOYSA-N 0.000 claims description 4
• YAPPRYLJJFBFDI-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[3,3-dimethyl-1-(2-methylsulfonylethoxy)cyclohexyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(OCCS(C)(=O)=O)CCCC(C)(C)C1 YAPPRYLJJFBFDI-UHFFFAOYSA-N 0.000 claims description 4
• YBHDUCZJAFZXMS-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[3,3-dimethyl-1-[2-(methylamino)ethoxy]cyclohexyl]methyl]-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)N1CC1(OCCNC)CCCC(C)(C)C1 YBHDUCZJAFZXMS-UHFFFAOYSA-N 0.000 claims description 4
• QGGHHQCYXAURKG-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[3-(dimethylamino)phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CN(C)C1=CC=CC(CN2N=CC(=C2)C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 QGGHHQCYXAURKG-UHFFFAOYSA-N 0.000 claims description 4
• CDWPYUDXUVZEQD-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 CDWPYUDXUVZEQD-UHFFFAOYSA-N 0.000 claims description 4
• BHCPDYBYBYGVKV-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[3-[(dimethylamino)methyl]phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CN(C)CC1=CC=CC(CN2N=CC(=C2)C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 BHCPDYBYBYGVKV-UHFFFAOYSA-N 0.000 claims description 4
• ZQODOCMKSVFZBR-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[3-[2-(dimethylamino)ethoxy]phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CN(C)CCOC1=CC=CC(CN2N=CC(=C2)C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 ZQODOCMKSVFZBR-UHFFFAOYSA-N 0.000 claims description 4
• OYUHQFCBQJGJSZ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=CC(OCCN(C)C)=CC=C1CN1N=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 OYUHQFCBQJGJSZ-UHFFFAOYSA-N 0.000 claims description 4
• SWGHOHOEWIDJCI-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1CN1N=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 SWGHOHOEWIDJCI-UHFFFAOYSA-N 0.000 claims description 4
• PZPKMRVORBEWFE-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-benzyl-3-(hydroxymethyl)-5-methylpyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(CO)=NN1CC1=CC=CC=C1 PZPKMRVORBEWFE-UHFFFAOYSA-N 0.000 claims description 4
• JANVUPFLGQSVCZ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[2-cyano-3-[cyclohexylsulfonyl(methyl)amino]phenyl]pyridine-2-carboxylic acid Chemical compound C=1C=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C#N)C=1N(C)S(=O)(=O)C1CCCCC1 JANVUPFLGQSVCZ-UHFFFAOYSA-N 0.000 claims description 4
• GWKZRGVRRJRVKW-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[2-methyl-3-(n-methylanilino)phenyl]pyridine-2-carboxylic acid Chemical compound C=1C=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)C=1N(C)C1=CC=CC=C1 GWKZRGVRRJRVKW-UHFFFAOYSA-N 0.000 claims description 4
• JQPXGABBAARRLZ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[2-methyl-3-[methyl-(1-methylcyclohexanecarbonyl)amino]phenyl]pyridine-2-carboxylic acid Chemical compound C=1C=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)C=1N(C)C(=O)C1(C)CCCCC1 JQPXGABBAARRLZ-UHFFFAOYSA-N 0.000 claims description 4
• CGYKENUKXWMQSX-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[3-(3,3-dimethylcyclohexyl)oxy-2-methylphenyl]pyridine-2-carboxylic acid Chemical compound C1=CC=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=C1OC1CCCC(C)(C)C1 CGYKENUKXWMQSX-UHFFFAOYSA-N 0.000 claims description 4
• VWKSVGWIWBXZHT-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[3-(4-chlorophenoxy)phenyl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=1)=CC=CC=1OC1=CC=C(Cl)C=C1 VWKSVGWIWBXZHT-UHFFFAOYSA-N 0.000 claims description 4
• SRMMAHLQXRMAJV-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[3-(4-nitrophenoxy)phenyl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=1)=CC=CC=1OC1=CC=C([N+]([O-])=O)C=C1 SRMMAHLQXRMAJV-UHFFFAOYSA-N 0.000 claims description 4
• NZIZLWUOJUCRDB-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[3-(cyclohexylamino)-2-methylphenyl]pyridine-2-carboxylic acid Chemical compound C1=CC=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=C1NC1CCCCC1 NZIZLWUOJUCRDB-UHFFFAOYSA-N 0.000 claims description 4
• PGJLLHFSFHKZFB-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[3-(cyclohexylmethoxy)-2-methylphenyl]pyridine-2-carboxylic acid Chemical compound C1=CC=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=C1OCC1CCCCC1 PGJLLHFSFHKZFB-UHFFFAOYSA-N 0.000 claims description 4
• TYVVJJITOAHSEK-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[3-(cyclohexylmethyl)-2-methylphenyl]pyridine-2-carboxylic acid Chemical compound C1=CC=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=C1CC1CCCCC1 TYVVJJITOAHSEK-UHFFFAOYSA-N 0.000 claims description 4
• JLJIISHGYOZQJK-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[3-[(3,3-dimethylcyclohexyl)-methylamino]-2-methylphenyl]pyridine-2-carboxylic acid Chemical compound C=1C=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)C=1N(C)C1CCCC(C)(C)C1 JLJIISHGYOZQJK-UHFFFAOYSA-N 0.000 claims description 4
• QFDMSUUMMGGQNA-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[3-[cyclohexanecarbonyl(methyl)amino]-2-methylphenyl]pyridine-2-carboxylic acid Chemical compound C=1C=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C(C)C=1N(C)C(=O)C1CCCCC1 QFDMSUUMMGGQNA-UHFFFAOYSA-N 0.000 claims description 4
• AIBPITJIFDVGNJ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[4-(cyclohexylmethoxy)-2-methylphenyl]pyridine-2-carboxylic acid Chemical compound C=1C=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=CC=1OCC1CCCCC1 AIBPITJIFDVGNJ-UHFFFAOYSA-N 0.000 claims description 4
• JPAAIJREVBXWLR-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-cyano-1-(cyclohexylmethyl)-2-methylpyrrol-3-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=C(C#N)N1CC1CCCCC1 JPAAIJREVBXWLR-UHFFFAOYSA-N 0.000 claims description 4
• ZSPPFPZZYXTXSZ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-cyano-1-[[1-(2-methoxyethoxy)cycloheptyl]methyl]-2-methylpyrrol-3-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=C(C#N)N1CC1(OCCOC)CCCCCC1 ZSPPFPZZYXTXSZ-UHFFFAOYSA-N 0.000 claims description 4
• GTQOBRXIUSEPME-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-cyano-1-[[1-(dimethylamino)cyclohexyl]methyl]-2-methylpyrrol-3-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=C(C#N)N1CC1(N(C)C)CCCCC1 GTQOBRXIUSEPME-UHFFFAOYSA-N 0.000 claims description 4
• AWWJGXLEOUSGCD-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-cyano-2-methyl-1-[(1-morpholin-4-ylcyclohexyl)methyl]pyrrol-3-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=C(C#N)N1CC1(N2CCOCC2)CCCCC1 AWWJGXLEOUSGCD-UHFFFAOYSA-N 0.000 claims description 4
• VWVLZOGKYVADBL-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-cyano-2-methyl-1-[(1-piperidin-1-ylcyclohexyl)methyl]pyrrol-3-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=C(C#N)N1CC1(N2CCCCC2)CCCCC1 VWVLZOGKYVADBL-UHFFFAOYSA-N 0.000 claims description 4
• CXLVLOGFZIAGJS-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-(oxan-2-ylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1CCCCO1 CXLVLOGFZIAGJS-UHFFFAOYSA-N 0.000 claims description 4
• GXSMBNWKCTYDEF-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-(oxan-3-ylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1CCCOC1 GXSMBNWKCTYDEF-UHFFFAOYSA-N 0.000 claims description 4
• XKWOGPRRCOBWST-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-[(1-methylcyclohexyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(C)CCCCC1 XKWOGPRRCOBWST-UHFFFAOYSA-N 0.000 claims description 4
• GLPWLJNLOVKWQF-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-[(2,6,6-trimethyloxan-2-yl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(C)CCCC(C)(C)O1 GLPWLJNLOVKWQF-UHFFFAOYSA-N 0.000 claims description 4
• JFCXBWXVXSHFIH-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-[(6-pyrrolidin-1-ylpyridin-2-yl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC(N=1)=CC=CC=1N1CCCC1 JFCXBWXVXSHFIH-UHFFFAOYSA-N 0.000 claims description 4
• WTTPODKXFFUDLT-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-[[1-(2-morpholin-4-yl-2-oxoethoxy)cyclohexyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(OCC(=O)N2CCOCC2)CCCCC1 WTTPODKXFFUDLT-UHFFFAOYSA-N 0.000 claims description 4
• YXBZXVKUEAJBAQ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-[[1-(3-morpholin-4-ylpropoxy)cycloheptyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(OCCCN2CCOCC2)CCCCCC1 YXBZXVKUEAJBAQ-UHFFFAOYSA-N 0.000 claims description 4
• IOCQNUBZJDEJHU-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-[[2-(2-morpholin-4-ylethoxy)phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1=CC=CC=C1OCCN1CCOCC1 IOCQNUBZJDEJHU-UHFFFAOYSA-N 0.000 claims description 4
• PANNEEFYXZRCCJ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-[[2-(3-morpholin-4-ylpropoxy)phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1=CC=CC=C1OCCCN1CCOCC1 PANNEEFYXZRCCJ-UHFFFAOYSA-N 0.000 claims description 4
• XMPCYQGJBQMNTD-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-[[2-(oxan-4-ylmethoxy)phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1=CC=CC=C1OCC1CCOCC1 XMPCYQGJBQMNTD-UHFFFAOYSA-N 0.000 claims description 4
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 4
• REGIYSKTNLQTJH-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-2-[5-[1-[(1-methoxy-3,3-dimethylcyclohexyl)methyl]-5-methylpyrazol-4-yl]-6-(methylsulfonylcarbamoyl)pyridin-2-yl]-3,4-dihydro-1h-isoquinoline-8-carboxamide Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(=O)NS(C)(=O)=O)=C(C)N1CC1(OC)CCCC(C)(C)C1 REGIYSKTNLQTJH-UHFFFAOYSA-N 0.000 claims description 4
• XLJBTMOBHNCGBL-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-2-[5-[1-[[1-(2-methoxyethyl)cycloheptyl]methyl]-5-methylpyrazol-4-yl]-6-(methylsulfonylcarbamoyl)pyridin-2-yl]-3,4-dihydro-1h-isoquinoline-8-carboxamide Chemical compound N1=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(=O)NS(C)(=O)=O)=C(C)N1CC1(CCOC)CCCCCC1 XLJBTMOBHNCGBL-UHFFFAOYSA-N 0.000 claims description 4
• TVUSAEFDJXAFJR-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-2-[5-[5-cyano-1-(cyclohexylmethyl)-2-methylpyrrol-3-yl]-6-(methylsulfonylcarbamoyl)pyridin-2-yl]-3,4-dihydro-1h-isoquinoline-8-carboxamide Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(=O)NS(C)(=O)=O)C=C(C#N)N1CC1CCCCC1 TVUSAEFDJXAFJR-UHFFFAOYSA-N 0.000 claims description 4
• ZRMZDOZYFNCSPI-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzylindazol-4-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=1C=N2)=CC=CC=1N2CC1=CC=CC=C1 ZRMZDOZYFNCSPI-UHFFFAOYSA-N 0.000 claims description 3
• UEKDPMLKBHDDEM-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzylindazol-5-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 UEKDPMLKBHDDEM-UHFFFAOYSA-N 0.000 claims description 3
• UDVFOYKTMOICPN-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[2-(cyclohexylmethyl)-3,4-dihydro-1h-isoquinolin-6-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=C1CC2)=CC=C1CN2CC1CCCCC1 UDVFOYKTMOICPN-UHFFFAOYSA-N 0.000 claims description 3
• KYJMLYBOYHSDKK-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[2-(pyridin-2-ylmethyl)-3,4-dihydro-1h-isoquinolin-6-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C=C1CC2)=CC=C1CN2CC1=CC=CC=N1 KYJMLYBOYHSDKK-UHFFFAOYSA-N 0.000 claims description 3
• 208000004736 B-Cell Leukemia Diseases 0.000 claims 2
• RXYRSQZDQIZAKD-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[3-methyl-1-[(6-pyrrolidin-1-ylpyridin-2-yl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C(C)=NN1CC(N=1)=CC=CC=1N1CCCC1 RXYRSQZDQIZAKD-UHFFFAOYSA-N 0.000 claims 1
• 125000000753 cycloalkyl group Chemical group 0.000 abstract description 97
• 230000000694 effects Effects 0.000 abstract description 18
• 239000000126 substance Substances 0.000 abstract description 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
• 150000002391 heterocyclic compounds Chemical class 0.000 abstract 2
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 289
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 289
• 125000000623 heterocyclic group Chemical group 0.000 description 183
• 239000000460 chlorine Substances 0.000 description 140
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 115
• 125000001072 heteroaryl group Chemical group 0.000 description 108
• 125000003118 aryl group Chemical group 0.000 description 90
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 89
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 88
• 229910052757 nitrogen Inorganic materials 0.000 description 59
• 125000003342 alkenyl group Chemical group 0.000 description 51
• 125000000304 alkynyl group Chemical group 0.000 description 51
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 49
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 47
• 239000003112 inhibitor Substances 0.000 description 33
• 150000002390 heteroarenes Chemical class 0.000 description 31
• 239000000203 mixture Substances 0.000 description 30
• 125000004429 atom Chemical group 0.000 description 29
• 150000001924 cycloalkanes Chemical class 0.000 description 29
• 150000001925 cycloalkenes Chemical class 0.000 description 29
• 239000002207 metabolite Substances 0.000 description 28
• 229940002612 prodrug Drugs 0.000 description 26
• 239000000651 prodrug Substances 0.000 description 26
• 125000004366 heterocycloalkenyl group Chemical group 0.000 description 24
• 125000004432 carbon atom Chemical group C* 0.000 description 23
• 108090000623 proteins and genes Proteins 0.000 description 23
• 102000004169 proteins and genes Human genes 0.000 description 23
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
• 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 20
• 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 20
• 201000010099 disease Diseases 0.000 description 20
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 19
• 125000006413 ring segment Chemical group 0.000 description 19
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 17
• 229910052805 deuterium Inorganic materials 0.000 description 17
• 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 16
• 230000002424 anti-apoptotic effect Effects 0.000 description 15
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
• 150000001721 carbon Chemical group 0.000 description 14
• 230000027455 binding Effects 0.000 description 13
• GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 description 13
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
• YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 12
• 125000004452 carbocyclyl group Chemical group 0.000 description 12
• 102000051485 Bcl-2 family Human genes 0.000 description 10
• 108700038897 Bcl-2 family Proteins 0.000 description 10
• 102000055574 bcl-2 Homologous Antagonist-Killer Human genes 0.000 description 10
• 102000055102 bcl-2-Associated X Human genes 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 102000014914 Carrier Proteins Human genes 0.000 description 9
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 9
• 108700000711 bcl-X Proteins 0.000 description 9
• 102000055104 bcl-X Human genes 0.000 description 9
• 108091008324 binding proteins Proteins 0.000 description 9
• 125000003367 polycyclic group Chemical group 0.000 description 9
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 8
• 239000000427 antigen Substances 0.000 description 8
• 108091007433 antigens Proteins 0.000 description 8
• 102000036639 antigens Human genes 0.000 description 8
• 229940043355 kinase inhibitor Drugs 0.000 description 8
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 8
• 238000011282 treatment Methods 0.000 description 8
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 7
• 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 7
• 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 7
• 125000001188 haloalkyl group Chemical group 0.000 description 7
• 125000005549 heteroarylene group Chemical group 0.000 description 7
• 150000002430 hydrocarbons Chemical group 0.000 description 7
• 230000003211 malignant effect Effects 0.000 description 7
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 102100035548 Protein Bop Human genes 0.000 description 6
• 108050008794 Protein Bop Proteins 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 229910052717 sulfur Inorganic materials 0.000 description 6
• HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 5
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
• 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 5
• 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 5
• 230000005775 apoptotic pathway Effects 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000001965 increasing effect Effects 0.000 description 5
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 5
• 239000011593 sulfur Substances 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 4
• 108091000080 Phosphotransferase Proteins 0.000 description 4
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
• 239000012190 activator Substances 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 230000000155 isotopic effect Effects 0.000 description 4
• 102000020233 phosphotransferase Human genes 0.000 description 4
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• 230000000861 pro-apoptotic effect Effects 0.000 description 4
• 102000004196 processed proteins & peptides Human genes 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 229930195734 saturated hydrocarbon Natural products 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• PVCULFYROUOVGJ-UHFFFAOYSA-N 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea Chemical compound CNC(=O)N(S(C)(=O)=O)N(S(C)(=O)=O)CCCl PVCULFYROUOVGJ-UHFFFAOYSA-N 0.000 description 3
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
• OMYYCDWHOXJERQ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-(1-benzyl-3-cyanopyrazol-4-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(C(=N1)C#N)=CN1CC1=CC=CC=C1 OMYYCDWHOXJERQ-UHFFFAOYSA-N 0.000 description 3
• MXEQADTUEHZJIP-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(oxan-4-ylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1CCOCC1 MXEQADTUEHZJIP-UHFFFAOYSA-N 0.000 description 3
• CXFUEKBYSQDJNH-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-(piperidin-4-ylmethyl)pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1CCNCC1 CXFUEKBYSQDJNH-UHFFFAOYSA-N 0.000 description 3
• QOPPDAFHRPLEHJ-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(2-morpholin-4-ylsulfonylphenyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1S(=O)(=O)N1CCOCC1 QOPPDAFHRPLEHJ-UHFFFAOYSA-N 0.000 description 3
• LQDYWDZCLGSDRP-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[(3,3-dimethylcyclohexyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1C(C)(C)CCCC1CN1N=CC(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)=C1 LQDYWDZCLGSDRP-UHFFFAOYSA-N 0.000 description 3
• ACKCMZMYRXOHHH-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[1-[[3-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=NOC(C=2C=C(CN3N=CC(=C3)C=3C(=NC(=CC=3)N3CC4=C(C(=O)NC=5SC6=CC=CC=C6N=5)C=CC=C4CC3)C(O)=O)C=CC=2)=N1 ACKCMZMYRXOHHH-UHFFFAOYSA-N 0.000 description 3
• XIFDSCJJCFTYSL-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[5-methyl-1-[(1-morpholin-4-ylcyclohexyl)methyl]pyrazol-4-yl]pyridine-2-carboxylic acid Chemical compound CC1=C(C=2C(=NC(=CC=2)N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)C(O)=O)C=NN1CC1(N2CCOCC2)CCCCC1 XIFDSCJJCFTYSL-UHFFFAOYSA-N 0.000 description 3
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 102000001301 EGF receptor Human genes 0.000 description 3
• 108060006698 EGF receptor Proteins 0.000 description 3
• 235000019487 Hazelnut oil Nutrition 0.000 description 3
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
• 229940049595 antibody-drug conjugate Drugs 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 239000003719 aurora kinase inhibitor Substances 0.000 description 3
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 235000019437 butane-1,3-diol Nutrition 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• 239000004359 castor oil Substances 0.000 description 3
• 235000019438 castor oil Nutrition 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 235000005687 corn oil Nutrition 0.000 description 3
• 239000002285 corn oil Substances 0.000 description 3
• 235000012343 cottonseed oil Nutrition 0.000 description 3
• 239000002385 cottonseed oil Substances 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
• 235000019441 ethanol Nutrition 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 229960004945 etoricoxib Drugs 0.000 description 3
• 230000014509 gene expression Effects 0.000 description 3
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
• 239000010468 hazelnut oil Substances 0.000 description 3
• 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
• 229960001680 ibuprofen Drugs 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 210000001700 mitochondrial membrane Anatomy 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• 210000000214 mouth Anatomy 0.000 description 3
• 125000001624 naphthyl group Chemical group 0.000 description 3
• 229950004847 navitoclax Drugs 0.000 description 3
• JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 3
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
• 231100001143 noxa Toxicity 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• 229960000435 oblimersen Drugs 0.000 description 3
• MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• 239000004006 olive oil Substances 0.000 description 3
• 235000008390 olive oil Nutrition 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• 229940121649 protein inhibitor Drugs 0.000 description 3
• 239000012268 protein inhibitor Substances 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 230000025915 regulation of apoptotic process Effects 0.000 description 3
• 239000002336 ribonucleotide Substances 0.000 description 3
• AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
• 229960005486 vaccine Drugs 0.000 description 3
• 230000035899 viability Effects 0.000 description 3
• 125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 2
• 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 2
• 229940058015 1,3-butylene glycol Drugs 0.000 description 2
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
• UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 2
• 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 2
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
• XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
• XIZMJORTNFIVRF-UHFFFAOYSA-N 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-3-[6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-2-carboxypyridin-3-yl]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)C=3C=CC=C4CCN(CC4=3)C=3N=C(C(=CC=3)C=3C(=NC(=CC=3)N3CC4=C(C(=O)NC=5SC6=CC=CC=C6N=5)C=CC=C4CC3)C(O)=O)C(=O)O)=NC2=C1 XIZMJORTNFIVRF-UHFFFAOYSA-N 0.000 description 2
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
• KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
• 102000009058 Death Domain Receptors Human genes 0.000 description 2
• 108010049207 Death Domain Receptors Proteins 0.000 description 2
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 2
• 102000010638 Kinesin Human genes 0.000 description 2
• 108010063296 Kinesin Proteins 0.000 description 2
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 101710105759 Major outer membrane porin Proteins 0.000 description 2
• 101710164702 Major outer membrane protein Proteins 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
• 108091028664 Ribonucleotide Proteins 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
• 102000002938 Thrombospondin Human genes 0.000 description 2
• 108060008245 Thrombospondin Proteins 0.000 description 2
• 108091008605 VEGF receptors Proteins 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 230000008484 agonism Effects 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
• 230000008485 antagonism Effects 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 239000000611 antibody drug conjugate Substances 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 239000003443 antiviral agent Substances 0.000 description 2
• 238000003782 apoptosis assay Methods 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
• 229960002707 bendamustine Drugs 0.000 description 2
• YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
• 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 229960003008 blinatumomab Drugs 0.000 description 2
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
• 150000001723 carbon free-radicals Chemical class 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 2
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
• 229960000684 cytarabine Drugs 0.000 description 2
• 229960002448 dasatinib Drugs 0.000 description 2
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 229960001433 erlotinib Drugs 0.000 description 2
• NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
• 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 125000001786 isothiazolyl group Chemical group 0.000 description 2
• 125000000842 isoxazolyl group Chemical group 0.000 description 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
• 229960004891 lapatinib Drugs 0.000 description 2
• 229950002884 lexatumumab Drugs 0.000 description 2
• KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
• 230000037353 metabolic pathway Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
• 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
• 108091070501 miRNA Proteins 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 2
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
• IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 2
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
• 229910052697 platinum Inorganic materials 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 229940069328 povidone Drugs 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000005522 programmed cell death Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 230000003331 prothrombotic effect Effects 0.000 description 2
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
• 125000005494 pyridonyl group Chemical group 0.000 description 2
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
• XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
• 230000020129 regulation of cell death Effects 0.000 description 2
• 125000002652 ribonucleotide group Chemical group 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
• WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 239000008159 sesame oil Substances 0.000 description 2
• 235000011803 sesame oil Nutrition 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 230000008054 signal transmission Effects 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 235000010356 sorbitol Nutrition 0.000 description 2
• 239000003549 soybean oil Substances 0.000 description 2
• 235000012424 soybean oil Nutrition 0.000 description 2
• 229960000894 sulindac Drugs 0.000 description 2
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
• 229960000235 temsirolimus Drugs 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 230000030968 tissue homeostasis Effects 0.000 description 2
• UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 229960000575 trastuzumab Drugs 0.000 description 2
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 229940094060 tykerb Drugs 0.000 description 2
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 239000010497 wheat germ oil Substances 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• RIWLPSIAFBLILR-WVNGMBSFSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2r,3s)-2-[[(2s)-2-[[2-[[2-[acetyl(methyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethy Chemical compound CC(=O)N(C)CC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC RIWLPSIAFBLILR-WVNGMBSFSA-N 0.000 description 1
• WZRFLSDVFPIXOV-LRQRDZAKSA-N (2s)-1-[(2s)-2-cyclohexyl-2-[[(2s)-2-(methylamino)propanoyl]amino]acetyl]-n-(4-phenylthiadiazol-5-yl)pyrrolidine-2-carboxamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C(=O)NC2=C(N=NS2)C=2C=CC=CC=2)CCCCC1 WZRFLSDVFPIXOV-LRQRDZAKSA-N 0.000 description 1
• BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 1
• MHFUWOIXNMZFIW-WNQIDUERSA-N (2s)-2-hydroxypropanoic acid;n-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound C[C@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 MHFUWOIXNMZFIW-WNQIDUERSA-N 0.000 description 1
• ZFKBWSREWJOSSJ-VIFPVBQESA-N (2s)-6,8-dichloro-2-(trifluoromethyl)-2h-chromene-3-carboxylic acid Chemical compound ClC1=CC(Cl)=C2O[C@H](C(F)(F)F)C(C(=O)O)=CC2=C1 ZFKBWSREWJOSSJ-VIFPVBQESA-N 0.000 description 1
• UFPFGVNKHCLJJO-SSKFGXFMSA-N (2s)-n-[(1s)-1-cyclohexyl-2-[(2s)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C=2SC=C(N=2)C(=O)C=2C=CC(F)=CC=2)CCCCC1 UFPFGVNKHCLJJO-SSKFGXFMSA-N 0.000 description 1
• HCSMRSHIIKPNAK-LSAVBLLPSA-N (2s)-n-[(1s)-2-[(3ar,7as)-6-(2-phenylethyl)-3,3a,4,5,7,7a-hexahydro-2h-pyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H]3CN(CCC=4C=CC=CC=4)CC[C@@H]3CC2)CCCCC1 HCSMRSHIIKPNAK-LSAVBLLPSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• 125000006718 (C3-C7) heterocycloalkenyl group Chemical group 0.000 description 1
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
• 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
• SWQQELWGJDXCFT-PNHWDRBUSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide Chemical compound C#CC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SWQQELWGJDXCFT-PNHWDRBUSA-N 0.000 description 1
• WPHKIQPVPYJNAX-UHFFFAOYSA-N 1-[4-[4-amino-7-[1-(2-hydroxyethyl)pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-3-(3-fluorophenyl)urea Chemical compound C1=2SC=C(C=3C=CC(NC(=O)NC=4C=C(F)C=CC=4)=CC=3)C=2C(N)=NC=C1C=1C=NN(CCO)C=1 WPHKIQPVPYJNAX-UHFFFAOYSA-N 0.000 description 1
• 125000006083 1-bromoethyl group Chemical group 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• CZDWSKBKCZWXFI-UHFFFAOYSA-N 1-morpholin-4-yl-3-[4-oxo-3-[4-[2-oxo-2-(4-propan-2-ylpiperazin-1-yl)ethoxy]phenyl]-1h-indeno[1,2-c]pyrazol-5-yl]urea Chemical compound C1CN(C(C)C)CCN1C(=O)COC1=CC=C(C=2C=3C(=O)C4=C(NC(=O)NN5CCOCC5)C=CC=C4C=3NN=2)C=C1 CZDWSKBKCZWXFI-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• KUFRQPKVAWMTJO-QSTRRNJOSA-N 17-dmag Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-QSTRRNJOSA-N 0.000 description 1
• YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
• LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
• XNTLXAUHLBBEKP-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound O=C1C(OCCC(C)(O)C)=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=NN1C1=CC=C(F)C(F)=C1 XNTLXAUHLBBEKP-UHFFFAOYSA-N 0.000 description 1
• PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 1
• RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 1
• QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• HUSXNIFVQFHSEA-UHFFFAOYSA-N 2-hydroxypropanoic acid;hydrochloride Chemical compound Cl.CC(O)C(O)=O HUSXNIFVQFHSEA-UHFFFAOYSA-N 0.000 description 1
• CMRFJAMFEWYMKE-UHFFFAOYSA-N 2-oxaadamantane Chemical group C1C(O2)CC3CC1CC2C3 CMRFJAMFEWYMKE-UHFFFAOYSA-N 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
• BJVRNXSHJLDZJR-UHFFFAOYSA-N 3-(1-methyl-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-6-yl)phenol Chemical compound N1=C2N(C)N=CC2=C(N2CCOCC2)N=C1C1=CC=CC(O)=C1 BJVRNXSHJLDZJR-UHFFFAOYSA-N 0.000 description 1
• RQUCIYUYJHVVIL-UHFFFAOYSA-N 3-[[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]methyl]-1h-pyridazin-6-one Chemical compound CN1C(C(=O)C=2C=CC(Cl)=CC=2)=C(C)C=C1CC=1C=CC(=O)NN=1 RQUCIYUYJHVVIL-UHFFFAOYSA-N 0.000 description 1
• 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
• 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
• 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 1
• WJRRGYBTGDJBFX-UHFFFAOYSA-N 4-(2-methyl-3-propan-2-yl-4-imidazolyl)-N-(4-methylsulfonylphenyl)-2-pyrimidinamine Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=N1 WJRRGYBTGDJBFX-UHFFFAOYSA-N 0.000 description 1
• XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
• ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
• HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 1
• HEROWGICZZJWKP-UHFFFAOYSA-N 4-pyrrol-1-ylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C=CC=C1 HEROWGICZZJWKP-UHFFFAOYSA-N 0.000 description 1
• WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 1
• HUNAOTXNHVALTN-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)pyrazole-3-carboxamide Chemical compound CCNC(=O)C1=NNC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C1=CC=C(OC)C=C1 HUNAOTXNHVALTN-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• DOCINCLJNAXZQF-LBPRGKRZSA-N 6-fluoro-3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=C(F)C=C2C(=O)N1C1=CC=CC=C1 DOCINCLJNAXZQF-LBPRGKRZSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• NKGPJODWTZCHGF-UHFFFAOYSA-N 9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound OC1C(O)C(CO)OC1N1C(NC=NC2=S)=C2N=C1 NKGPJODWTZCHGF-UHFFFAOYSA-N 0.000 description 1
• OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
• BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
• QYZOGCMHVIGURT-UHFFFAOYSA-N AZD-1152 Chemical compound N=1C=NC2=CC(OCCCN(CCO)CC)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 QYZOGCMHVIGURT-UHFFFAOYSA-N 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 108090000644 Angiozyme Proteins 0.000 description 1
• 108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 description 1
• 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 1
• 241001120493 Arene Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 description 1
• QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 description 1
• 229940122035 Bcl-XL inhibitor Drugs 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 244000056139 Brassica cretica Species 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 102000003952 Caspase 3 Human genes 0.000 description 1
• 108090000397 Caspase 3 Proteins 0.000 description 1
• 102100026550 Caspase-9 Human genes 0.000 description 1
• 108090000566 Caspase-9 Proteins 0.000 description 1
• 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 1
• 101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 1
• 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
• 102100025832 Centromere-associated protein E Human genes 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 102100021906 Cyclin-O Human genes 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 102100030497 Cytochrome c Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010075031 Cytochromes c Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
• 108010002156 Depsipeptides Proteins 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 102000007989 Effector Caspases Human genes 0.000 description 1
• 108010089510 Effector Caspases Proteins 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 108700000266 GSK923295 Proteins 0.000 description 1
• RVAQIUULWULRNW-UHFFFAOYSA-N Ganetespib Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O RVAQIUULWULRNW-UHFFFAOYSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
• LLEUXCDZPQOJMY-AAEUAGOBSA-N Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(O)=O)=CNC2=C1 LLEUXCDZPQOJMY-AAEUAGOBSA-N 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 108090000353 Histone deacetylase Proteins 0.000 description 1
• 102000003964 Histone deacetylase Human genes 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000914247 Homo sapiens Centromere-associated protein E Proteins 0.000 description 1
• 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
• 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
• UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
• CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010025327 Lymphopenia Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
• 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
• 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
• 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 1
• 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 239000004909 Moisturizer Substances 0.000 description 1
• 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 108010072915 NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt Proteins 0.000 description 1
• KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 1
• ZAHXYMFVNNUHCP-UHFFFAOYSA-N Naphazoline nitrate Chemical group O[N+]([O-])=O.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 ZAHXYMFVNNUHCP-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
• 101100528525 Prochlorococcus marinus (strain SARG / CCMP1375 / SS120) rnc gene Proteins 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• JHBIMJKLBUMNAU-UHFFFAOYSA-N SC-58125 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 JHBIMJKLBUMNAU-UHFFFAOYSA-N 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 1
• 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 1
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 244000269722 Thea sinensis Species 0.000 description 1
• 241000534944 Thia Species 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 229930189037 Trapoxin Natural products 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• 241000209140 Triticum Species 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 229940127507 Ubiquitin Ligase Inhibitors Drugs 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• XJXKGUZINMNEDK-GPJOBVNKSA-L [(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](CN)[C@@H](CN)O1 XJXKGUZINMNEDK-GPJOBVNKSA-L 0.000 description 1
• XMYKNCNAZKMVQN-NYYWCZLTSA-N [(e)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
• XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 229950009084 adecatumumab Drugs 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 229940023476 agar Drugs 0.000 description 1
• 125000001980 alanyl group Chemical group 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229940110282 alimta Drugs 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 229940098174 alkeran Drugs 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical class 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 125000004686 alkyl sulfanyl alkyl group Chemical group 0.000 description 1
• 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229940024545 aluminum hydroxide Drugs 0.000 description 1
• 229950010817 alvocidib Drugs 0.000 description 1
• BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
• 125000000732 arylene group Chemical group 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 239000005441 aurora Substances 0.000 description 1
• 229940120638 avastin Drugs 0.000 description 1
• 229960003005 axitinib Drugs 0.000 description 1
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• 125000002785 azepinyl group Chemical group 0.000 description 1
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 125000004602 benzodiazinyl group Chemical group N1=NC(=CC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• 229940110331 bextra Drugs 0.000 description 1
• BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 229950004271 brostallicin Drugs 0.000 description 1
• RXOVOXFAAGIKDQ-UHFFFAOYSA-N brostallicin Chemical compound C1=C(C(=O)NCCN=C(N)N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3N(C=C(NC(=O)C(Br)=C)C=3)C)C=2)C)=CN1C RXOVOXFAAGIKDQ-UHFFFAOYSA-N 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 229960002412 cediranib Drugs 0.000 description 1
• 229940047495 celebrex Drugs 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• IQCIQDNWBGEGRL-UHFFFAOYSA-N chembl1614651 Chemical compound O=C1C2=C(O)C=CC(O)=C2N2N=C(CNCCO)C3=CC=C(NCCCN)C1=C32 IQCIQDNWBGEGRL-UHFFFAOYSA-N 0.000 description 1
• ZFVRYNYOPQZKDG-MQMHXKEQSA-N chembl560895 Chemical compound O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1N[C@H]1CC[C@H](O)CC1 ZFVRYNYOPQZKDG-MQMHXKEQSA-N 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 229950007276 conatumumab Drugs 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
• 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
• 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 230000001461 cytolytic effect Effects 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 229950006418 dactolisib Drugs 0.000 description 1
• JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 229940070230 daypro Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 229960003314 deracoxib Drugs 0.000 description 1
• 229940051427 deramaxx Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
• 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• 229960000616 diflunisal Drugs 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 125000005972 dihydrochromenyl group Chemical group 0.000 description 1
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
• 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• DCSRPHQBFSYJNN-UHFFFAOYSA-L disodium 4-[(2-arsonophenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].Oc1c(N=Nc2ccccc2[As](O)(O)=O)c2ccc(cc2cc1S([O-])(=O)=O)S([O-])(=O)=O DCSRPHQBFSYJNN-UHFFFAOYSA-L 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229940072701 dolobid Drugs 0.000 description 1
• 238000004980 dosimetry Methods 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 229940121647 egfr inhibitor Drugs 0.000 description 1
• 229940120655 eloxatin Drugs 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229950006835 eptaplatin Drugs 0.000 description 1
• 229940082789 erbitux Drugs 0.000 description 1
• 125000001033 ether group Chemical group 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• 229960005167 everolimus Drugs 0.000 description 1
• 230000028023 exocytosis Effects 0.000 description 1
• 229940065410 feldene Drugs 0.000 description 1
• 229950000133 filanesib Drugs 0.000 description 1
• LLXISKGBWFTGEI-FQEVSTJZSA-N filanesib Chemical compound C1([C@]2(CCCN)SC(=NN2C(=O)N(C)OC)C=2C(=CC=C(F)C=2)F)=CC=CC=C1 LLXISKGBWFTGEI-FQEVSTJZSA-N 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229940020967 gemzar Drugs 0.000 description 1
• 230000030279 gene silencing Effects 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 229940080856 gleevec Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 1
• QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
• 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 239000000677 immunologic agent Substances 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 229940124541 immunological agent Drugs 0.000 description 1
• 229940089536 indocin Drugs 0.000 description 1
• 125000004926 indolenyl group Chemical group 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000012444 intercalating antibiotic Substances 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
• 125000005969 isothiazolinyl group Chemical group 0.000 description 1
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 229960004752 ketorolac Drugs 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229950000340 laromustine Drugs 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 229950008991 lobaplatin Drugs 0.000 description 1
• 229940063718 lodine Drugs 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 229960000994 lumiracoxib Drugs 0.000 description 1
• 231100001023 lymphopenia Toxicity 0.000 description 1
• 229940124302 mTOR inhibitor Drugs 0.000 description 1
• 229950000547 mafosfamide Drugs 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 239000002679 microRNA Substances 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
• VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
• 229950010913 mitolactol Drugs 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000001333 moisturizer Effects 0.000 description 1
• 229940072709 motrin Drugs 0.000 description 1
• ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• SMFXSYMLJDHGIE-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide Chemical compound N=1C=2SN=C(C)C=2C(=O)N(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C=C1 SMFXSYMLJDHGIE-UHFFFAOYSA-N 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 229940090008 naprosyn Drugs 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
• 229960001420 nimustine Drugs 0.000 description 1
• 229960003753 nitric oxide Drugs 0.000 description 1
• XHWRWCSCBDLOLM-UHFFFAOYSA-N nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
• 229950000891 nolatrexed Drugs 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 235000021313 oleic acid Nutrition 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 125000005880 oxathiolanyl group Chemical group 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 125000003585 oxepinyl group Chemical group 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 229960004662 parecoxib Drugs 0.000 description 1
• TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 235000021400 peanut butter Nutrition 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
• 229930192851 perforin Natural products 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 230000008823 permeabilization Effects 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229950005566 picoplatin Drugs 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• 239000002770 polo like kinase inhibitor Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• MREOOEFUTWFQOC-UHFFFAOYSA-M potassium;5-chloro-4-hydroxy-1h-pyridin-2-one;4,6-dioxo-1h-1,3,5-triazine-2-carboxylate;5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione Chemical compound [K+].OC1=CC(=O)NC=C1Cl.[O-]C(=O)C1=NC(=O)NC(=O)N1.O=C1NC(=O)C(F)=CN1C1OCCC1 MREOOEFUTWFQOC-UHFFFAOYSA-M 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000005412 pyrazyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000003410 quininyl group Chemical group 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 229960002185 ranimustine Drugs 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 108091006084 receptor activators Proteins 0.000 description 1
• 108091006082 receptor inhibitors Proteins 0.000 description 1
• 230000009711 regulatory function Effects 0.000 description 1
• 229940087462 relafen Drugs 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• OAKGNIRUXAZDQF-TXHRRWQRSA-N retaspimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OAKGNIRUXAZDQF-TXHRRWQRSA-N 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229960000329 ribavirin Drugs 0.000 description 1
• HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
• NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
• 229960000311 ritonavir Drugs 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
• HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
• 229960000215 ruxolitinib Drugs 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 229960000953 salsalate Drugs 0.000 description 1
• 190014017285 satraplatin Chemical compound 0.000 description 1
• 229960005399 satraplatin Drugs 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
• BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 125000003375 sulfoxide group Chemical group 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229950007866 tanespimycin Drugs 0.000 description 1
• 229940120982 tarceva Drugs 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 229960001674 tegafur Drugs 0.000 description 1
• WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000002769 thiazolinyl group Chemical group 0.000 description 1
• 125000003777 thiepinyl group Chemical group 0.000 description 1
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
• 125000005032 thiofuranyl group Chemical group S1C(=CC=C1)* 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
• 229960001017 tolmetin Drugs 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 229940019127 toradol Drugs 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 108010060597 trapoxin A Proteins 0.000 description 1
• 229940066958 treanda Drugs 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 229960005526 triapine Drugs 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical class OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical class [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 229960002004 valdecoxib Drugs 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 229960003636 vidarabine Drugs 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 229940087652 vioxx Drugs 0.000 description 1
• 229940063674 voltaren Drugs 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
• QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
• 229940053867 xeloda Drugs 0.000 description 1